🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07797660
Starting soon Observational

A Study for Postoperative Delirium in Older Patients With Intracranial Tumors

NCT07797660 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Observational
Started
2026-08-30
Last updated
2026-09-01

Condition(s) studied

DeliriumBrain Tumor

Study summary

Postoperative delirium is a common acute central nervous system syndrome, which often occurs 1-5 days after surgery. Postoperative delirium can prolong the length of hospital stay, increase the mortality rate, and is also associated with long-term postoperative cognitive dysfunction. However, the pathogenesis of postoperative delirium in elderly patients undergoing neurosurgical procedures, who are at high risk for ostoperative delirium, remains unclear. This study aims to elucidate the underlying mechanisms of postoperative delirium in this population and inform the development of effective prevention and treatment strategies.

Eligibility

Sex
ALL
Min age
60 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing elective craniotomy for intracranial tumour resection * Patients who will provide written informed consent Exclusion Criteria: * Patients with severe preoperative cognitive impairment precluding subsequent assessments * History of psychotropic medication use * Previous history of neurosurgical operation * Severe bradycardia (heart rate \< 40 beats per minute) * Sick-sinus syndrome or atrioventricular block of grade Ⅱ or above * Severe hepatic insufficiency (Child-Pugh grade C) * Renal failure requiring renal replacement therapy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tian Tan Hospital, Capital Medical University Beijing Beijing Municipality

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07797660 on ClinicalTrials.gov ↗ ← All trials in China